Tagged with CNS

Opinion Cerecin’s Charles Stacey looks at the large unmet medical need in diseases of the central nervous system (CNS), the looming socioeconomic burden that these diseases represent, and the innovative solutions needed to counter it.   45 percent of the patient population in neurology remains unserved – they either have no…

Turkey From collaborating with authorities to tackling awareness surrounding mental illnesses, Altan Gorseval, country manager of Lundbeck Turkey, paints an accurate picture of the company’s dedication to improving mental health and patient outcomes in the country. What have been your strategic priorities for Lundbeck Turkey over the past two years? Our…

Brazil Jun Eguti, general manager of Grünenthal Brazil, highlights the global transformation Grünenthal has undergone in the past two years, the huge potential the Brazilian affiliate has to become one of the largest in LatAm and the exciting product pipeline the affiliate has in Pain Management, Women’s Health, CNS and Gout…

Tunisia Habib Toumi, CEO of the Tunisian National Social Security Fund (CNSS), discusses implementing universal healthcare coverage, restoring the financial equilibrium of the fund, and managing the continuous improvement of services provided in the CNSS policlinics. Can you describe the operational characteristics of the Tunisian National Social Security Fund (CNSS)? “Concerning…

Taiwan Ming-Kuei Jang, founder and CEO of Aprinoia, a very promising Taiwan-based company focused on the development of groundbreaking imaging tracers and therapeutics targeting tau-related neurodegenerative diseases, provides insights into the company’s rapid development over the past two years, its R&D strategy, and its eagerness to partner with both academia and…

Taiwan With more than 100 peer-reviewed articles published and more than ten thousand citations, Guochuan Emil Tsai, founder and CEO of SyneuRx and Professor at the department of Psychiatry and Behavioral sciences at the University of California, Los Angeles (UCLA), is an internationally reputed scientist in neurosciences and brain disorders, whose…

Switzerland The CEO of Max Zeller, a Swiss Phytopharmaceutical company, highlights the immense benefits his products have and furthermore discusses the company’s internationalization strategy. Mr Boonen, you joined Max Zeller in June 1999 and have spent almost all your professional career here. How have you seen the company evolve over time…

pharma The general manager of Ali Raif, Muzaffer Bal illustrates the various success factors that allowed the company to secure market leading positions within Turkey and across Europe, while also highlighting how the company has adapted its portfolio to shifting market dynamics. Muzaffer, as an introduction for our readers, please provide…

R&D Lundbeck Turkey’s managing director discusses CNS and mental illness in Turkey, and their recent development of manufacturing operations in Turkey for their new product. Given this specialization in and deep knowledge of CNS, how would you assess the Turkish medical systems’ ability to handle mental illness? First of all, when…

CNS diseases Oscar Parra, general manager at Lundbeck Mexico, explains the seriousness of CNS diseases in increasingly urbanized countries and the impact they can have on the productivity of the Mexican workforce. The last time we met was in 2012. How have central nervous system (CNS) diseases evolved in Mexico over this…

CNS Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research.   What have been some of the biggest successes in the last three to four years for this affiliate? The greatest…

CNS Lundbeck’s country manager gives a thorough overview of CNS disorders in Malaysia and states: “It is important to remind everyone that mental health conditions or brain diseases are not to be overlooked.” While this is a challenge, it also represents an opportunity for Lundbeck to provide best-in-line products to patients.…